2020-2026年醫藥授權協議趨勢

本報告對全球醫藥產業的授權協議進行了全面分析。報告專為業務拓展、許可、法律和策略專業人士設計，深入剖析了企業如何建立許可合作關係、協商財務條款以及共享研發和商業化權利。

這份經過全面修訂和更新的報告包含了2020年至2026年間簽署的2700多份許可協議的詳細信息，全面展現了醫藥行業的許可活動。每份協議記錄均包含可用的財務條款，並在公開的情況下提供指向線上協議記錄和已提交給監管機構的協議文件的連結。

透過整合詳細的交易數據、財務基準以及對實際協議文件的訪問，本報告為您提供寶貴的見解，幫助您評估潛在合作夥伴、制定許可協議並協商更有利的條款。

主要優勢

• 顯著縮短研究時間

集中存取超過 2,700 份授權協議，無需再搜尋多個資料庫、新聞稿和監管文件。

• 許可協議結構基準分析

了解製藥公司如何建構其許可合作關係，包括研發責任、區域權利和商業化安排。

• 財務條款分析

審查已揭露的付款結構，例如預付款、里程碑付款和特許權使用費，以準確評估許可協議的價值。

• 存取實際合約文件

審查已向美國證券交易委員會 (SEC) 提交的實際許可協議（如有），以深入了解實際協議背後的合約條款。

• 識別擁有有效許可協議的公司

識別在醫藥許可領域最活躍的公司，並分析其合作策略。

• 追蹤許可趨勢

分析自 2020 年以來依公司、治療領域和技術劃分的授權活動，以了解產業合作策略的演變。

目錄

摘要整理

第一章：引言

第二章：許可交易趨勢

• 許可協議的定義
• 2020年以來授權協議的趨勢
  • 依年份
  • 依研發階段
  • 依行業
  • 依治療領域
  • 依技術型
  • 最活躍的公司
• 簽訂許可合作協議的原因
• 許可協議的未來

第三章：許可協議結構概述

• 許可協議的結構許可協議

第四章 主要授權協議

• 主要授權協議：依金額排序

第五章：最活躍的25項授權協議

• 最活躍的25項授權協議

第六章：合作協議目錄：附協議文件

• 合作協議：附協議文件
• 合約目錄
• 合約目錄 - 依公司（A-Z）排序
• 合約目錄 - 依治療領域排序
• 合約目錄 - 依技術排序
• 關於Biopharma Research Ltd
• 當前合作關係
• 當前協議
• 近期合作報告標題

Benchmark Licensing Partnerships Across the Global Pharmaceutical Industry

Request our free report sample

The Licensing Deals in Pharmaceuticals 2020-2026 report provides a comprehensive analysis of licensing agreements across the global pharmaceutical industry. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.

Fully revised and updated, the report includes details of more than 2,700 licensing deals announced between 2020 and 2026, providing an extensive view of licensing activity across the pharmaceutical sector. Each deal record includes financial terms where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

By combining detailed deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating potential partners, structuring licensing agreements, and negotiating stronger deal terms.

Key Benefits

• Save Significant Research Time

Access over 2,700 licensing deals in a single resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Licensing Deal Structures

Understand how pharmaceutical companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.

• Analyze Financial Terms with Confidence

Review disclosed payment structures such as upfront payments, milestone payments, and royalties, enabling accurate benchmarking of licensing deal value.

• Access Real Contract Documents

Where available, explore actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify Active Licensing Dealmakers

Discover which companies are most active in pharmaceutical licensing and analyze their partnership strategies.

• Track Licensing Trends

Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how industry partnering strategies are evolving.

What's Included in the Report

Analysis of pharmaceutical licensing dealmaking trends since 2020

Overview of licensing deal structures and financial models

Review of leading licensing deals by disclosed value

Profiles of the most active licensing dealmakers

Detailed analysis of deals by company, therapeutic area, and technology type

A comprehensive deal directory covering all licensing deals announced since 2020

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual licensing contracts, the report allows users to evaluate key partnership provisions such as:

• Rights granted or optioned under the license
• Upfront payments, milestone payments, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination provisions
• Why This Report Matters
• Licensing agreements are a cornerstone of pharmaceutical innovation, enabling companies to access new technologies, share development risk, and accelerate product commercialization.
• By providing comprehensive deal data, financial benchmarking, and access to real contract documents, this report delivers the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers